GlassScriptPhysician profile
Bryan Basil Brimhall
NPI 1902195753
$10,329.01
in general payments reported to CMS, 2019-2025
26 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $286 · 2021: $6,475 · 2022: $327 · 2023: $986 · 2024: $856 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,959.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $6,288.84 | 2021-2023 | Conmed Generators |
| Abbvie INC. | $1,789.98 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Genzyme Corporation | $313.86 | 2023-2025 | |
| Cook Medical LLC | $256.62 | 2019-2023 | Instinct |
| Takeda Pharmaceuticals U.S.A., INC. | $212.36 | 2021-2025 | Entyvio, Eohilia |
| Pfizer INC. | $152.91 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $124.09 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $116.47 | 2020-2024 | Ocaliva |
| Janssen Biotech, INC. | $103.58 | 2023-2025 | Simponi Aria, Simponi, Stelara |
| Olympus America INC. | $96.94 | 2019 | |
| Celgene Corporation | $96.56 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $92.65 | 2023-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $87.67 | 2024-2025 | Zenpep |
| Medtronic, INC. | $87.53 | 2021 | |
| Madrigal Pharmaceuticals | $85.83 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $84.71 | 2020 | |
| Ambu INC. | $83.87 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.48 | 2024 | Xifaxan |
| Ardelyx, INC. | $50.40 | 2023-2025 | Ibsrela |
| Digestive Care, INC. | $37.60 | 2024-2025 | Pertzye |
| Boston Scientific Corporation | $32.24 | 2019 | |
| Celltrion USA INC. | $19.28 | 2025 | Vegzelma |
| Lucid Diagnostics INC. | $15.16 | 2023 | |
| Merck Sharp & Dohme LLC | $14.82 | 2022 | |
| Alfasigma USA, INC. | $14.76 | 2020 | |
| Phathom Pharmaceuticals, INC. | $11.80 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Brimhall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.